Premenstrual Syndrome
Scenar and
Antihomotoxic Preparations in PMS Therapy
Authors:
Maijushko O, Repilo U, Garmonia Centre, Kiev, Ukraine.
Premenstrual syndrome (or premenstrual tension, PMS, PMT) involves disturbances of various
systems -- psycho-emotional, vegetative, vascular, metabolic and endocrine -- manifested in the second phase of the
premenstrual cycle. An essential role for the origin of PMS is assigned to the hormone prolactin.
Aim: to explore the effectiveness of Scenar both as a monotherapy and in
combination with the "HEEL" preparations from Germany on women with PMS.
Material and methods: the clinical effectiveness of the therapy was
evaluated in 27 women with PMS at the Garmonia clinic in Kiev, Ukraine. Psycho-emotional disturbances, neurological
symptoms and changes in the mammary glands prevailed. Extra-genital pathology was found in 89% of the women.
The level of prolactin in the blood was assessed by radio-immuno assay before and after the
therapy. The patients were divided into two groups. In the first group, the treatment was carried out with Scenar
only according to the procedure "7 days before menstruation" for a period of three menstrual cycles. Additional
anti-homotoxic therapy was prescribed to the patients in the second group in the second phase of their cycles.
Results:
The results of treatment were assessed based on changes in the subjective feelings of the women,
and on the data from hormonal and ultrasound examinations. The therapy was considered effective when the symptoms
of PMS disappeared or diminished.
Symptoms: Full disappearance, or considerable decrease in PMS symptoms, was observed in 11
(78.5%) of the patients in the first group, and in 11 (92.3%) of those in the second group.
Prolactin levels: The level of prolactin before treatment was similar in both groups. Overall
levels showed prolactinemia up to 30 ng/ml, with an average of 28.1 ng/ml, in 11 of the women and average levels of
15.7 ng/ml (which is within normal limits) in the others. After three courses of therapy, prolactin levels in all
the women fell to an average of 12.2 ng/ml.
A normalising effect from the treatments was seen in disturbances of the menstrual cycle, hypo
menstrual syndrome, algo dysmenorrhea, and primary infertility. No side effects were observed.
Conclusions and recommendations:
1. Scenar and homotoxic therapy exert regulating influences on the prolaction concentration in
blood plasma in patients with PMS. The result may be due to both the influence on hypophysis-hypothalamic
structures (where prolactin is produced), and modification in sensitivity of the tissue-targets of prolactin.
2. The combination of Scenar and "HEEL" preparations shows higher clinical effectiveness in the
treatment of women with PMS.
3. The above results allow the use of Scenar therapy and antihomotoxic preparations (Mulimen,
Nervoheel, Hepeel) to be recommended to practitioners for the treatment of PMS to the given category of
patients.
|